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Abstract
The cowpox virus (CPV) glycoprotein serpin SPI-3, a functional protease inhibitor, and the viral hemagglutinin (HA) are required to
prevent fusion of wt CPV infected cells. SPI-3 and HA from CPV infected cells co-localize to the plasma membrane and are found in
extracellular enveloped virus (EEV). We also show that an N-terminal SPI-3 signal sequence, but not glycosylation, is required for
membrane localization and fusion inhibition. In the absence of HA (CPVHA), no SPI-3 is found on the membrane and infected cells fuse.
Conversely, HA from both wt CPV and CPVSPI-3 infections is on the membrane, indicating a requirement of HA for SPI-3 plasma
membrane localization. In the absence of HA, secretion of SPI-3 or SPI-3 N-glyc() was markedly enhanced, suggesting HA serves to retain
SPI-3 on the plasma membrane,thereby preventing cell fusion.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Serine proteinase inhibitors, or serpins, are found in
mammals, viruses, and plants, and regulate a variety of
biological processes, including inflammation, apoptosis,
and coagulation (Silverman et al., 2001). Inhibitory serpins
target specific proteinases through recognition of the P1
amino acid in the C-terminal reactive center loop (RCL) of
the serpin molecule (Djie et al., 1997; Dahlen et al., 1998).
Inhibition of the proteinase is achieved through the forma-
tion of a stable covalent complex of the serpin with the
proteinase (Wilczynska et al., 1997; Simonovic et al.,
2000). Functions other than proteinase inhibition have been
ascribed to serpins. For instance, several serpins have bind-
ing sites or other activity-associated domains that are not
within the RCL, including the nuclear localization signal of
MENT (Grigoryev et al., 1999) and the heparin binding site
of antithrombin (Whisstock et al., 2000).
Poxviruses are the only virus family known to encode
functional serpins. The orthopoxviruses, which include va-
riola, vaccinia, cowpox, and rabbitpox viruses, each encode
three serpins, SPI-1, SPI-2/crmA, and SPI-3. The SPI-1
protein has been shown to inhibit cathepsin G in vitro, and
this activity is dependent on the P1 amino acid of the serpin
(Moon et al., 1999). Deletion of the SPI-1 gene from rab-
bitpox virus (RPVSPI-1) results in a restricted host-range
phenotype whereby the mutant virus will no longer grow on
normally permissive cell lines (Brooks et al., 1995). This
restricted host range phenotype results in an apoptotic-like
process in non-permissive cells (Brooks et al., 1995) but
does not involve caspase activation (Moon et al., 1999). A
RPV recombinant expressing a SPI-1 gene with a mutated P1
residue has a host range phenotype similar to a deletion mutant
(Moon et al., 1999), indicating that the proteinase inhibitory
activity of SPI-1 is required for full host range of RPV.
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The SPI-2/crmA protein from cowpox virus (CPV) has
been shown to have anti-apoptotic activity in a number of
cell systems (Gagliardini et al., 1994; Ray and Pickup,
1996) and the purified protein has inhibitory activity against
several proteinases including caspases-1 and -8 (Ray et al.,
1992; Komiyama et al., 1994; Zhou et al., 1997) and gran-
zyme B (Quan et al., 1995). Chicken chorioallantoic mem-
branes infected with CPV deleted for crmA (CPVcrmA)
produce white, inflammatory pocks as opposed to the hem-
orrhagic, non-inflammatory, red pocks formed by infection
with wild-type CPV (Palumbo et al., 1989). Therefore,
SPI-2 has both anti-apoptotic and anti-inflammatory activ-
ities in vivo.
CPV and other poxviruses deleted for SPI-3
(CPVSPI-3) result in the fusion of infected CV-1 cells,
creating polykaryocytes (Turner and Moyer, 1992; Law and
Smith, 1992; Zhou et al., 1992). This fusion is indistinguish-
able from that resulting from the deletion of the CPV hem-
agglutinin (HA) gene (Turner and Moyer, 1992). The fusion
which results from disruption of either gene is believed to
be dependent on the 14kDa (p14) protein present on the
surface of intracellular mature virus (IMV) (Sodeik et al.,
1995), as a monoclonal antibody against p14 inhibits fusion
caused by deletion of either gene (Turner and Moyer, 1992).
Western Blot analysis of HA from CPVSPI-3 infected
cells demonstrates that the HA is stable and otherwise
unaffected by loss of the SPI-3 gene (Turner and Moyer,
1992). Co-infection of CPVSPI-3 with CPV deleted for
the HA gene (CPVHA) dramatically inhibits the amount of
fusion. Therefore, the CPV SPI-3 and HA proteins are both
involved in the inhibition of fusion in a common pathway
which involves p14. HA is present on the surface of extra-
cellular enveloped virus (EEV) of VV strain IHD-J but
absent from intracellular mature virus (IMV) (Payne and
Norrby, 1976).
The importance of serpin proteinase inhibitory activity
on the inhibition of fusion by SPI-3 has been analyzed in an
infected cell fusion assay (Turner and Moyer, 1995). Site
directed mutations within SPI-3’s RCL that included the
P1/P1 residues, P5 to P5 residues, and P17 to P10 residues
had no effect on fusion inhibition. As a result, it is very
likely that SPI-3 mediated inhibition of fusion does not
require proteinase inhibitory activity.
Subsequently, SPI-3 was purified and shown to effec-
tively inhibit urokinase-type and tissue-type plasminogen
activators as well as plasmin in enzymatic assays, with
inhibition constants ranging from 0.5–2 nM (Turner et al.,
2000). This activity was shown to be dependent on a P1
residue of Arg. Therefore, SPI-3 is a bifunctional protein,
having activity against proteinases in vitro and RCL-inde-
pendent fusion inhibition activity following infection in
vivo.
Overall, SPI-3 is biochemically very similar to the
SERP1 serpin of myxoma virus (MYX), although their
amino acid sequence similarity is fairly low. Both SPI-3 and
SERP1 have P1 residues of arginine and have similar pro-
teinase inhibition profiles and kinetic properties in vitro
(Lomas et al., 1993; Turner et al., 2000). However, the
SPI-3 protein is produced early in infection and is thought to
be intracellular, whereas the SERP1 protein is produced late
in infection and is secreted (Wang et al., 2000). SERP1 is
also a virulence factor in MYX, required for full develop-
ment of a lethal disease (Upton et al., 1990; Macen et al.,
1993). The ability of SPI-3 to substitute for SERP1 of MYX
has been analyzed (Wang et al., 2000). The SPI-3 ORF
replaced the SERP1 ORF in MYX, under the control of the
SERP1 promoter. Similarly, a CPV recombinant was de-
rived where the SPI-3 ORF was replaced by SERP1 under
control of the SPI-3 promoter. Infection of CV-1 cells with
CPVSPI-3::SERP1 caused cell fusion and SERP1 was
secreted. Therefore SERP1 cannot substitute for SPI-3 to
inhibit fusion.
MYXSERP1::SPI-3 infection of rabbits was just as
attenuated as MYX deleted for SERP1. Surprisingly, when
RK-13 cells were infected with MYXSERP1::SPI-3,
SPI-3 protein was now secreted, in contrast to wt CPV
infected cells, where only low levels of SPI-3 secretion are
observed. The secretion of SPI-3 by the MYX recombinant
was proposed to reflect either a modification of the cell’s
secretion machinery by MYX, or by the lack in MYX of a
protein present in CPV infections that served to retain SPI-3
within the infected cell (Wang et al., 2000).
While the SPI-3 protein has been extensively character-
ized in vitro, there is little information regarding intracel-
lular localization, and what features of the protein are re-
quired for control of fusion. To understand how SPI-3
inhibits fusion, we examined the SPI-3 protein for motifs
that might be important in fusion inhibition. SPI-3 protein
from infected cells has previously been shown to have
N-linked but not O-linked glycosylation (Turner and
Moyer, 1995). N-linked sugars have been shown to be
critical for a number of protein properties, including proper
folding and localization as well as providing contacts for
protein-protein interactions (Lis and Sharon, 1993; Dennis
et al., 1999). Sequence analysis of CPV SPI-3 indicates the
presence of 4 potential N-linked glycosylation sites fitting
the consensus sequence N-X-S/T, where X is any amino
acid except proline, at positions N161, N188, N232, and
N242. In addition to N-linked glycosylation, the first 15
amino acids of SPI-3 comprise a potential signal sequence
(SS), as determined by the computer signal sequence pre-
diction program SignalP v1.1 (Nielsen et al., 1997), which
if functional, would direct SPI-3 to the secretory pathway.
In this paper, we demonstrate that SPI-3 co-localizes to the
plasma membrane and to EEV like the viral HA, and that
the N-terminal signal sequence, but not N-linked glycosyl-
ation, is required for this localization and for fusion inhibi-
tion. Surprisingly, the viral HA was needed for normal
localization of SPI-3 to the plasma membrane and deletion
of HA leads to markedly increased secretion of SPI-3. These
results suggest a novel requirement of HA for SPI-3 plasma
membrane localization resulting in fusion inhibitory activ-
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ity. Implications for the localization of SPI-3 on cellular
membranes and virions are discussed.
Results
Creation of SPI-3 genes with mutated N-linked
glycosylation sites or lacking an N-terminal signal
sequence
To investigate whether N-linked glycosylation of SPI-3
was required for fusion inhibition, each of SPI-3’s 4 pre-
dicted N-linked glycosylation sites (N-X-S/T, where X is
any amino acid except proline) was mutated separately by
site directed mutagenesis to the following amino acids:
N161D, N188D, N232D, N242H. In addition, a final mutant
was created which contained mutations in all four potential
N-linked glycosylation sites (SPI-3 N-glyc()) (Fig. 1). To
address the effects of mutations in potential N-linked gly-
cosylation sites, cells were first infected with vTF7-3, a
vaccinia virus expressing the T7 RNA polymerase, trans-
fected with plasmids containing a PT7-driven wt or mutant
SPI-3 gene, then 35S radiolabeled proteins were resolved by
SDS–PAGE (Fig. 2). Mutation of a single glycosylation site
would be expected to decrease the apparent molecular
weight of SPI-3 by 1.5 kDa to 3 kDa.
Infection with vTF7-3 results in shutoff of host protein
synthesis and the appearance of viral specific proteins. This
pattern of protein expression is observed when empty vector
(control) is transfected into vTF7-3 infected cells (lane 2)
compared to uninfected cells (lane 1). After transfection
with a plasmid containing the wt SPI-3 gene, two radiola-
beled bands appear at about 51 kDa and 49 kDa (lane 3,
asterisks), presumably reflecting complete and partially gly-
cosylated forms of SPI-3 due to overexpression of the pro-
tein. It has previously been demonstrated that when SPI-3 is
expressed in a similar fashion but in the presence of tuni-
camycin, an N-linked glycosylation inhibitor, that the 51
and 49 kDa SPI-3 bands are reduced to 42 kDa, approxi-
mately the predicted molecular weight of the unglycosy-
lated protein (Turner and Moyer, 1995). Therefore, the
higher molecular weight forms seen in lane 3 are a result of
N-linked glycosylation. Transfection with each of the SPI-3
N-linked glycosylation mutant genes N188D, N232D, and
N242H (lanes 5–7, respectively) lowers the molecular
weight of the two bands seen with wt SPI-3 by approxi-
mately 1.5–3 kDa, as expected for the loss of N-linked
glycan at the mutated site. The N161D mutation resulted in
the appearance of only a single, lower molecular weight
band at 48 kDa (lane 4). The reduced SPI-3 molecular
weights of each of the single glycosylation mutants (lanes
4–7) are consistent with elimination of a functional N-
linked glycosylation site. SPI-3 N-glyc() with all four
sites mutated (lane 8) runs with the lowest apparent molec-
ular weight (approximately 42 kDa), suggesting loss of all
N-linked glycan addition, as this protein exhibits the same
electrophoretic mobility as SPI-3 synthesized in vitro where
there is no glycosylation (data not shown). In fact, all SPI-3
N-linked glycosylation mutant proteins synthesized in vitro
have the same molecular weight by SDS–PAGE as wt SPI-3
protein made in vitro (data not shown). Therefore, the en-
gineered amino acid mutations in SPI-3 do not result in
changes in SPI-3 mobility when subject to SDS–PAGE.
Since SPI-3 has been shown previously to be N-linked
glycosylated when expressed in the context of vaccinia
virus, we can conclude that the molecular weight changes
observed in Fig. 2 are the result of loss of N-linked glycans.
Therefore, this assay demonstrates that all four potential
N-linked glycosylation sites of SPI-3 are used in vivo.
Since SPI-3 is glycosylated, it is likely that SPI-3 enters
the secretory pathway, which would allow for N-linked
glycan addition in the ER/Golgi apparatus. Entry of SPI-3
into the secretory pathway would be facilitated by the pres-
ence of a potential N-terminal signal sequence. To address
whether SPI-3s entry into the secretory pathway is neces-
Fig. 2. Utilization of the four potential N-linked glycosylation sites of
SPI-3. Cells were mock infected (lane 1) or infected with vTF7-3 (lanes
2–9). Samples in lanes 2–9 were then transfected with plasmid DNAs as
follows: lane 2, pTM1 (vector); lane 3, pTM1-SPI-3; lane 4, pTM1-SPI-3
N161D; lane 5, pTM1-SPI-3 N188D; lane 6, pTM1-SPI-3 N232D; lane 7,
pTM1-SPI-3 N242H; lane 8, pTM1-SPI-3 N-glyc(); lane 9, pTM1-SPI-3
SS(). Radiolabeled proteins in extracts were visualized following SDS–
PAGE and autoradiography. Asterisks denote the positions of PT7-driven
wild-type and mutant SPI-3 proteins which were readily visible over the
background of vaccinia virus proteins.
Fig. 1. Schematic representation of the CPV SPI-3 protein. A putative
signal sequence (SS) is found from amino acids 1 to 15 at the N-terminus
of the SPI-3 protein. Four potential N-linked glycosylation sites that fit the
consensus sequence N-X-S/T, where X is any amino acid except proline,
are found at the following asparagines (N): N161, N188, N232, and N242.
The Reactive Center Loop (RCL), containing the P1 amino acid which
determines the specificity of the serpin, is found at the C-terminus of the
protein. The SPI-3 N-glyc() protein has all four N-linked glycosylation
sites mutated as follows: N161D, N188D, N232D, N242H. The SPI-3
SS() protein lacks the signal sequence (AA 1–15) which is replaced by
an initiating methionine. The SPI-3 SS() protein retains the 4 potential
N-linked glycosylation sites.
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sary for fusion inhibition, a mutant SPI-3 SS() was created
which eliminated the first 15 amino acids (a predicted signal
sequence) and placed a methionine before the 16th amino
acid (Fig. 1). Transfection of SPI-3 SS() into vTF7-3
infected cells (Fig. 2, lane 9) results in a form of SPI-3
similar to the molecular weight of SPI-3 N-glyc() (lane 8),
due to lack of glycosylation. Slight differences in molecular
weights between these two proteins may be due to differ-
ential cleavage of the signal sequence of SPI-3 N-glyc() in
cells compared to the engineered cleavage of SPI-3 SS().
SPI-3 with either mutated N-linked glycosylation sites or
lacking the signal sequence retains the ability to complex
with urokinase in vitro
Unglycosylated SPI-3 has previously been demonstrated
to act as a potent serine proteinase inhibitor in vitro (Turner
et al., 2000). To determine whether the mutations in either
SPI-3 N-glyc() and/or SPI-3 SS() affect the ability of
SPI-3 to act as a serine proteinase inhibitor, in vitro 35S-
labeled wt SPI-3, SPI-3 N-glyc() and SPI-3 SS() were
incubated with human low molecular weight urokinase, and
the products analyzed by SDS-PAGE (Fig. 3). Note that
labeled SPI-3 in this assay is not glycosylated and therefore
any differences in serpin function are due to the engineered
amino acid mutations. In the presence of the serine protein-
ase urokinase, wt SPI-3 forms a readily detectable higher
molecular weight complex which is resistant to boiling in
the presence of SDS, a characteristic of active inhibitory
serpins (lane 2). We quantified the amount of complex
formed in the presence of urokinase as a percent of the input
serpin without urokinase. In the presence of urokinase,
11.8% of wt SPI-3 is in the higher molecular weight com-
plex. Less SPI-3 N-glyc()/urokinase complex is found
compared to wt SPI-3 (6.6%), whereas the levels of SPI-3
SS()/urokinase complex are somewhat higher (23.0%).
Similar percentages of serpin-protease complex were con-
sistently found over 3 different concentrations of urokinase.
Therefore, while the mutations made in SPI-3 N-glyc()
may render the serpin less effective as an inhibitor com-
pared to either wt SPI-3 or SPI-3 SS(), these mutations do
not intrinsically destroy serpin activity.
Characterization of CPV recombinants for expression of
SPI-3
To address whether SPI-3 N-glyc() or SPI-3 SS()
retained the ability to inhibit cell-cell fusion, CPV recom-
binants were generated where the native SPI-3 gene was
replaced with a mutant SPI-3 gene to generate either CPV
SPI-3 N-glyc() or CPV SPI-3 SS(). These constructs
were examined by Western Blot analysis to ensure the
stability and appropriate molecular weight of the mutant
SPI-3 proteins. CV-1 cells were infected with wt CPV,
CPVSPI-3, CPV SPI-3 N-glyc(), and CPV SPI-3 SS()
and infected cell proteins were analyzed by Western Blot
using a monoclonal antibody against SPI-3 (Fig. 4). No
SPI-3 protein was detected from CPVSPI-3 cell pellets
(lane 1). There is a background protein of approximately 53
kDa in pellets from CPVSPI-3 infected cells. This protein
is present in Western Blot analysis of non-infected cell
pellets as well (data not shown). SPI-3 protein from wt CPV
infected cells (lane 2) presents as a diffuse immunoreactive
band between 50 and 55 kDa, indicative of variable N-
linked glycosylation as previously described (Turner and
Moyer, 1995). SPI-3 protein from a CPV SPI-3 N-glyc()
infection is a single immunoreactive band (lane 3), at a
lower molecular weight than SPI-3 protein from a wt CPV
infection, a result of the loss of N-linked glycans. After
infection with CPV SPI-3 SS(), SPI-3 protein was also
detected as a single band (lane 4), and migrated at the same
position as SPI-3 N-glyc() protein (lane 3). With the loss
of the signal sequence, we hypothesize that SPI-3 would no
longer have access to the secretory pathway, would not be
glycoyslated but would exist as a cytoplasmic non-glycosy-
lated protein. Therefore, each SPI-3 protein, either mutant
or wild-type, ran at the expected molecular weight based on
predicted functions of N-linked glycosylation sites and the
signal sequence, in that loss of N-linked glycosylation sites
Fig. 4. Western Blot analysis of CPV recombinants expressing mutant
SPI-3. Cells were infected with virus as indicated and infected cell proteins
were separated by SDS–PAGE followed by Western Blot analysis using an
anti-SPI-3 mAb. Lane 1, CPVSPI-3 infected cells; lane 2, wt CPV
infected cells; lane 3, CPV SPI-3 N-glyc() infected cells; lane 4, CPV
SPI-3 SS() infected cells.
Fig. 3. SPI-3 mutants retain the ability to complex with urokinase in vitro.
Radiolabeled wt or mutant SPI-3 protein synthesized in vitro was incubated
in the absence (lanes 1, 3, and 5) or the presence (lanes 2, 4, and 6) of
human low molecular weight urokinase. Higher molecular weight serpin-
proteinase complexes were then visualized following SDS–PAGE and
autoradiography. The following plasmids were used to generate radiola-
beled SPI-3 protein: lanes 1 and 2, pTM1-SPI-3; lanes 3 and 4, pTM1-
SPI-3 N-glyc(); lanes 5 and 6, pTM1-SPI-3 SS(). The lower arrow
indicates the position of the uncomplexed 35S-labeled SPI-3 protein and the
upper arrow indicates the position of higher molecular weight SPI-3-
urokinase complexes.
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or the signal sequence of SPI-3 resulted in the protein
having a lower apparent molecular weight from infected
cells.
The signal sequence but not N-linked glycan addition of
SPI-3 is necessary for fusion inhibition in vivo
Deletion of either the SPI-3 or the HA gene from CPV
results in cell-cell fusion (Turner and Moyer, 1992). The
recombinants CPV SPI-3 N-glyc() and CPV SPI-3 SS()
were analyzed for the ability to inhibit fusion by infecting
CV-1 cells and evaluating the resulting plaques at 2 days
post infection (p.i.) for cell-cell fusion (Fig. 5). Wt CPV
infection demonstrated characteristic cytopathic effect with
individual cell rounding but no cell-cell fusion. Infection
with CPVSPI-3 and CPVHA gave extensive cell-cell
fusion as expected, with syncytial plaques containing giant
multi-nucleated cells. CPV SPI-3 N-glyc() infection gave
no cell-cell fusion, indicating N-linked glycosylation per se
is not required for fusion inhibition. However, infection
with CPV SPI-3 SS() resulted in the formation of syncytia
and therefore the signal sequence of SPI-3 is necessary for
inhibition of cell fusion. We next studied the effects of the
N-glyc() and SS() mutations of SPI-3 on localization.
SPI-3 localizes to the Golgi apparatus early in infection
The presence of N-linked glycans suggests that SPI-3
must pass through the ER/Golgi apparatus. Therefore, we
examined the cellular localization of SPI-3 at different times
post infection. Cells were infected with wt CPV and
CPVSPI-3 and were analyzed by immunofluorescence at 4
or 6 h p.i. (Fig. 6). At 3 h p.i., no expression of SPI-3
was noted from wt CPV infected cells (data not shown). At
four h p.i., some cells infected with wt CPV showed detect-
able levels of SPI-3 protein (green, Fig. 6A), presumably
as expression of SPI-3 is just beginning. Cells infected
with fusogenic CPVSPI-3 have not yet fused at 4 h p.i.,
and therefore the gross morphology of cells infected with wt
and mutant viruses was identical at this time. SPI-3 was
present in wt CPV-infected cells at 4 h p.i. in a perinuclear
location (Fig. 6A), similar to that of the mannose-6-phos-
phate receptor (red), a marker for the Golgi compartment
(Fig. 6B). In fact, at early times p.i., SPI-3 co-localized
with the mannose-6-phosphate receptor as evidenced by
the yellow color (Fig. 6C) after merging of the green and
red channels. Note that SPI-3 was not detected in cells
infected with CPVSPI-3, but infected cells still labeled
with the mannose-6-phosphate receptor (panels D–E). Cells
shown in panels D and E are shown at a lower magnifica-
tion to demonstrate a greater number of cells that are not
positive for SPI-3 at this time point. SPI-3 did not co-
localize at 4 h after wt CPV infection with an ER marker,
disulfide isomerase (data not shown). All wt CPV infected
cells express SPI-3 by 6 h p.i. (panel F) in a manner
consistent with not only Golgi localization, but also some
plasma membrane localization. Co-localization with the
mannose-6-phosphate receptor showed that SPI-3 protein is
Fig. 5. The effects of SPI-3 mutations on cell fusion. Cells were infected under liquid with the following viruses: wt CPV, CPVSPI-3, CPVHA, CPV SPI-3
N-glyc(), CPV SPI-3 SS(), and photographed at 2 days p.i.
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present in the Golgi apparatus at early times p.i., as expected
for a glycoprotein.
SPI-3 co-localizes with HA to the plasma membrane late
in infection
Cell-cell fusion is a late event and can be inhibited with
the DNA replication inhibitor AraC (Law and Smith, 1992).
Therefore, to understand how SPI-3 inhibits fusion, it is
necessary to understand the protein’s localization both early
and late in infection. We infected CV-1 cells with wt and
mutant CPVs and examined them at 16 h p.i. (Fig. 7) for
localization of SPI-3. At 16 h p.i. in a wt CPV infection,
SPI-3 (green) clearly localizes to the plasma membrane
(Fig. 7A). At this time, HA (red) is also present on the
surface of infected cells (Fig. 7B). Merging of the images of
Fig 7A and B (yellow) shows co-localization of SPI-3 and
HA (Fig. 7C). The presence of SPI-3 on the cell membrane
is consistent with its role in blocking cell-cell fusion.
Given that CPV SPI-3 N-glyc() lacking N-linked gly-
cosylation is able to inhibit fusion, we wanted to determine
the localization of the SPI-3 N-glyc() protein. Immuno-
fluorescence demonstrated that SPI-3 N-glyc() was also
present at the surface of infected cells (Fig. 7D). The
amount of SPI-3 was somewhat reduced for CPV SPI-3
N-glyc() (Fig. 7D) compared with wt CPV (Fig. 7A),
suggesting that less protein was present on the surface,
although this apparent difference could also reflect more
efficient recognition of wt SPI-3 by the monoclonal anti-
body than the SPI-3 N-glyc() mutant. HA was present on
the cell membrane following CPV SPI-3 N-glyc() infec-
tion (Fig. 7E), and SPI-3 N-glyc() and HA again co-
localized (Fig. 7F). The fact that both wt SPI-3 and SPI-3
N-glyc() are at the cell surface is consistent with the
inhibition of cell-cell fusion by CPV SPI-3, and demon-
strates that SPI-3 can be localized correctly despite a com-
plete absence of N-linked glycosylation.
In cells infected with CPV SPI-3 SS(), SPI-3 did not
appear on the membrane (Fig. 7G–I). The merged red and
green channels (Fig. 7I) suggest that HA is at the surface but
SPI-3 is present in the cytoplasm as might be expected for
a protein lacking a signal sequence. The results of Fig. 7G–I
indicate that the SPI-3 signal sequence is required for mem-
brane localization. As previously noted, cells infected with
CPV SPI-3 SS() fuse (Fig. 5), again consistent with the
hypothesis that membrane localization of SPI-3 appears to
be necessary to prevent infected cell fusion. At late times
p.i., both fusion inhibitory proteins SPI-3 and HA localize to
the plasma membrane, even in the absence of N-linked
glycosylation of SPI-3. Finally, note that localization of HA
at the cell surface occurs in the absence of plasma mem-
brane SPI-3 (Fig. 7H).
Like HA, SPI-3 is a component of extracellular enveloped
virus (EEV) but not intracellular mature virus (IMV)
Since both SPI-3 and HA function to inhibit fusion and
we have demonstrated both proteins co-localize on infected
cells, we next asked whether SPI-3, like HA, could also be
found on extracellular enveloped virus (EEV). Poxvirus
virions are known to exist in several forms in the infected
cell. First, viral DNA and virion proteins are wrapped by
membrane to form intracellular mature virus (IMV), which
is fully infectious (Hollinshead et al., 1999; Griffiths et al.,
Fig. 6. Immunofluorescent localization of SPI-3 at early times post infection. Cells were infected with wt CPV (panels A–C and F) or CPVSPI-3 (panels
D–E) and were processed for immunofluorescence at 4 h p.i. (panels A–E) or 6 h p.i. (panel F). All cells were permeabilized with methanol and stained with
the DNA stain DAPI (blue) to visualize nuclei. Panels A, C, D, and F show FITC labeling of SPI-3 (green); panels B and E show Texas Red labeling of
M6PR, a Golgi marker (red); panel C is a merge of panels A and B (yellow indicates green and red overlap). Size bar in panel A applies to panels A, B,
C, and F. Size bar in panel D applies to panels D and E.
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2001a; Griffiths et al., 2001b). Some IMV are further envel-
oped by membranes from the trans-Golgi to form intracellular
enveloped virus (IEV) (van Eijl et al., 2000). These virions are
transported to the cell surface where they fuse with the plasma
membrane to form extracellular enveloped virus (EEV) (Smith
and Vanderplasschen, 1998). Since the HA protein has previ-
ously been shown to be present in vaccinia virus EEV but
absent from IMV (Payne and Norrby, 1976), we asked whether
SPI-3 could also be found on EEV.
To address this question, EEV and IMV from CPV and
CPVSPI-3 infected cells were tested for the presence of
SPI-3, B5R, a known EEV protein (Martinez Pomares et al.,
1993; Mathew et al., 1998), or the 14kDa (p14) protein, a
known IMV protein (Sodeik et al., 1995) using an electron
microscopy immunogold technique (Fig. 8). EEV prepared
from the medium of cells infected with wt CPV shows the
presence of the B5R protein (panel C), as expected. SPI-3
was present in wt CPV EEV (panel A), but not in wt CPV
IMV (panel D) nor on EEV or IMV purified from
CPVSPI-3 (panels B and E, respectively). On the other
hand, wt CPV IMV shows the presence of the 14 kDa
protein (panel F), as previously described (Sodeik et al.,
1995). Since EEV and IMV virions labeled with the known
EEV protein B5R and the known IMV 14kDa protein,
respectively, we can conclude that SPI-3, like the viral HA,
is a component of EEV, but not IMV.
Localization of SPI-3 to the plasma membrane requires
the HA protein
HA and SPI-3 both localize on the membrane of infected
cells as well as EEV and function to inhibit fusion (Figs. 7
and 8). We next analyzed the localization of each of these
proteins in the absence of the other. CV-1 cells were in-
fected with CPVSPI-3 or CPVHA, and examined at 16 h
p.i. (Fig. 9). SPI-3 (green) was not detected following in-
fection with CPVSPI-3 (data not shown) and large multi-
nucleated cells were evident by DAPI staining (panels A,
C). The HA protein (red) localized as expected to the
plasma membrane of these giant cells in the absence of
SPI-3 protein (panels B and C), in much the same fashion as
seen for wt CPV infected cells (Fig. 7B). When CV-1 cells
were infected with CPVHA, cell-cell fusion again results
(panels D–F). As expected, HA protein was not detectable
by immunofluorescence (data not shown). However, in the
Fig. 7. SPI-3 and HA co-localize to the membrane late in infection. Cells were infected with wt CPV (panels A–C), CPV SPI-3 N-glyc() (panels D–F),
or CPV SPI-3 SS() (panels G–I) for 16 h, then processed for immunofluorescence. Green color, FITC labeling of SPI-3; red color, Texas Red labeling of
HA; yellow color, overlap of green and red in merged image.
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absence of HA, SPI-3 is clearly not present at a significant
level on the surface of unpermeabilized cells, but instead is
present in punctate clumps of unknown localization (panels
E and F).
These results suggest that the correct localization of
SPI-3 on the plasma membrane directly or indirectly re-
quires the presence of HA protein. The HA might be nec-
essary for one of two functions. Either HA acts as a chap-
erone to help SPI-3 get from the Golgi to the plasma
membrane, or HA is required to retain SPI-3 on the surface
of the infected cell. If HA acts to retain SPI-3 on the cell
surface, we would expect to see enhanced secretion of SPI-3
into the supernatant of infected cells in the absence of HA.
The viral HA is required for retention of SPI-3 on the
plasma membrane of CPV infected cells
To determine if deletion of HA from CPV results in
enhanced secretion of SPI-3, CV-1 cells were infected with
Fig. 8. Detection of SPI-3 in CPV virions by immunogold electron microscopy. EEV (panels A–C) or IMV (panels D–F) of wt CPV (panels A, C, D, F),
or CPVSPI-3 (panels B, E) were probed with anti-SPI-3 mAb (panels A, B, D, E), anti-B5R mAb (panel C), or anti-14kDa mAbC3 (panel F), treated with
a 12 nm-gold-labeled secondary antibody, and then visualized by EM.
Fig. 9. SPI-3 plasma membrane localization requires the HA protein. Cells were infected with CPVSPI-3 (panels A–C) or CPVHA (panels D–F) for 16 h
and processed for immunofluorescence. All cells were stained with DAPI to visualize nuclei prior to analysis by fluorescence microscopy. Green color, FITC
labeling of SPI-3; red color, Texas Red labeling of HA; yellow color, overlap of green and red in merged images.
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wt CPV, CPVSPI-3, CPV SPI-3 N-glyc(), CPV SPI-3
SS(), and CPVHA, and both supernatant (S) and cell
pellet (P) fractions were analyzed by Western Blot using
monoclonal antibody against SPI-3 (Fig. 10) (Materials and
Methods). No SPI-3 protein was detected from CPVSPI-3
supernatant or cell pellets (lanes 1 and 2), although there is
a background band at approximately 50 kDa in pellets from
CPVSPI-3 infected cells. This band is present even fol-
lowing Western Blot analysis of non-infected cell pellets
(data not shown). SPI-3 protein from a wt CPV infection
was found in both supernatant (low levels) and cell pellets,
indicating that SPI-3 is poorly but partially secreted (lanes 3
and 4). SPI-3 protein from a CPVHA infection is of a
wild-type molecular weight distribution. However, far more
SPI-3 was secreted into the supernatant than from a wt CPV
infection (lanes 5 and 6). This result was independently
verified in three replicate experiments. These data suggest
that SPI-3 secretion or release from the membrane is inhib-
ited by HA.
After infection with CPV SPI-3 SS(), SPI-3 SS()
protein was predominantly detected in the cell pellet (lane
8) as was SPI-3 N-glyc() protein following CPV SPI-3
N-glyc() infection (lane 10). While both wt SPI-3 and
SPI-3 N-glyc() are found on the membrane, it is notewor-
thy that release of SPI-3 N-glyc() into the supernatant is
very low (compare lanes 3 and 9).
When the HA gene is deleted from CPV SPI-3
N-glyc(), SPI-3 is no longer found on the membrane by
immunofluorescence (data not shown) and instead is now
efficiently released from the surface of the infected cell
(compare Fig. 10, lanes 9–12). The collective results of
Figs. 9 and 10 suggest that HA is necessary not for traf-
ficking of SPI-3 to the membrane but rather for retention of
SPI-3 at the surface of the infected cell. In the absence of
HA, SPI-3 is not retained at the surface and the secretion of
SPI-3 becomes quite efficient and reminiscent of the exten-
sive secretion of SPI-3 seen when cells are infected with
myxoma virus containing SPI-3 (Wang et al., 2000).
Discussion
We demonstrate here that late in infection, SPI-3 is found
on the plasma membrane, consistent with its role in block-
ing cell-cell fusion. Cell surface localization of SPI-3 and
fusion inhibition occurred normally in the complete absence
of N-linked glycosylation, but both were abolished by de-
letion of the SPI-3 signal sequence. This result supports our
hypothesis that amino acids 1–15 of SPI-3 constitute an
active signal peptide that directs the protein to the secretory
pathway, and is consistent with our inability to purify SPI-3
by attaching a His tag to the extreme N-terminus (PC
Turner, unpublished results). When the SS was removed,
N-tagged His10-SPI-3 protein could be successfully purified
from infected cells (Turner et al., 2000).
The presence of a low level of SPI-3 in the supernatant
of wt CPV infected CV-1 cells (Fig. 10) is somewhat dif-
ferent from the result obtained by Wang et al. (2000), where
no secretion of SPI-3 was demonstrated from RK-13 cells
that had been infected with a vaccinia virus overexpressing
SPI-3. However, in the earlier work, SPI-3 was overex-
pressed and a polyclonal antisera was used rather than the
monoclonal antibody used here. Precedence for partial se-
cretion can be found among a number of serpin family
members, including the mammalian serpin maspin (Pem-
berton et al., 1997). The orientation of SPI-3 on the plasma
membrane was not determined; however, we hypothesize
that the majority of membrane associated SPI-3 protein is
outside the cell, as our monoclonal antibody recognizes
SPI-3 on the surface of unpermeabilized infected cells.
Experiments with Triton-X114 indicate that SPI-3 partitions
with the detergent phase (data not shown) and therefore may
be an integral membrane protein. However, the SPI-3 pro-
tein lacks a convincing transmembrane sequence by avail-
able prediction programs, unlike HA, which definitely ap-
pears to be an integral membrane protein.
When the SPI-3 gene is deleted, the HA protein localizes
to the plasma membrane normally, but when the HA protein
Fig. 10. HA is required for retention of SPI-3 on the plasma membrane. Cells were infected with the viruses indicated and cell equivalents of supernatant
(S) and pellet (P) were separated by SDS–PAGE followed by Western Blot analysis using an anti-SPI-3 mAb. Lane 1, supernatant from CPVSPI-3 infected
cells; lane 2, cell-associated pellet from CPVSPI-3 infected cells; lanes 3 and 4, supernatant and pellet respectively from wt CPV infected cells; lanes 5
and 6, supernatant and pellet from CPVHA infected cells; lanes 7 and 8, supernatant and pellet from CPV SPI-3 SS() infected cells; lanes 9 and 10,
supernatant and pellet from CPV SPI-3 N-glyc() infected cells; lanes 11 and 12, supernatant and pellet from CPV SPI-3 N-glyc() HA infected cells.
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is deleted, SPI-3 is no longer found on the plasma mem-
brane (Fig. 8). Deletion of the HA gene did not alter the
localization of the viral B5R protein as judged by immuno-
fluorescence (data not shown), indicating that the effect of
HA on SPI-3 localization is relatively specific. The greater
secretion of SPI-3 from cells infected with CPVHA com-
pared with wt CPV leads us to hypothesize that HA is
specifically required for retention of SPI-3 on the plasma
membrane. A similar phenomenon was seen when the ex-
tent of SPI-3 secretion was compared for CPV SPI-3 N-
glyc() and its HA derivative. The high level of SPI-3 in
the supernatant from cells infected with CPV SPI-3 N-
glyc() HA indicates that secretion does not require gly-
cosylation.
The increased secretion of CPV SPI-3 in the absence of
HA may explain the results of Wang et al. (2000), who
inserted the SPI-3 ORF into MYX in place of the native
serpin SERP1. Expression of SPI-3 from MYX gave effi-
cient secretion into the supernatant of infected cells. The
genomic sequence of MYX does not contain a homolog of
the orthopoxvirus HA protein (Cameron et al., 1999), and
we hypothesize that the lack of HA causes a failure to retain
SPI-3 at the surface of cells infected with MYX-SPI-3 and
instead produces secretion.
The role of SPI-3 present in EEV is unknown; however,
it is interesting to note that IMV contains the 14kDa fusion
protein on its outer surface whereas EEV contains the anti-
fusion SPI-3 and HA proteins. EEV and IMV enter unin-
fected cells by different mechanisms, although the exact
steps involved have not been determined (Locker et al.,
2000). Based on plaque development, SPI-3 does not seem
to be required for the infectivity of EEV in CV-1 cells. It
remains to be seen whether SPI-3 has a role in the specific
entry of EEV into certain cells. Another possibility is that
the presence of SPI-3 on EEV may prevent fusion of newly
made virions back to the infected cell. According to this
hypothesis, SPI-3 would be necessary to prevent superin-
fection of CPV infected cells. Experiments are currently
underway to address this question.
Finally, our results suggest how SPI-3 and HA might
function to inhibit infected cell fusion. Since cells infected
with CPVSPI-3 fuse, yet the HA protein is on the surface,
we can conclude that HA alone cannot act to inhibit fusion.
SPI-3 may be the actual anti-fusion protein, with HA merely
acting to ensure the correct localization of SPI-3 on the
surface of infected cells. According to this model, fusion
observed in the absence of HA may result from the failure
to retain SPI-3 at the cell surface. Alternatively, both SPI-3
and HA may be required at the cell surface for fusion
inhibition. Both models imply that HA and SPI-3 may
directly interact with one another, with HA acting as an
integral membrane protein anchor to retain SPI-3 on the
surface of the infected cell. We are currently investigating




CV-1 cells were obtained from the American Type Cul-
ture Collection (ATCC CCL-70) and were routinely main-
tained in GIBCO-BRL minimum essential medium (MEM)
with Earle’s salts supplemented with 5% fetal bovine serum,
2 mM glutamine, 50 U of penicillin G per ml, 50 g of
streptomycin per ml, 1 mM sodium pyruvate, and 0.1 mM
MEM nonessential amino acids (GIBCO-BRL, Rockville,
MD). wt CPV (Brighton Red strain) was obtained from
David Pickup (Duke University Medical Center).
CPVSPI-3 and CPVHA have been described previously
(Turner and Moyer, 1992).
Production of a monoclonal antibody to SPI-3
Purification of His-tagged SPI-3 protein lacking the N-
terminal signal sequence was carried out as previously de-
scribed (Turner et al., 2000). Monoclonal antibodies were
generated by the Hybridoma Core at the University of
Florida’s ICBR facility according to established protocols.
Monoclonal antibody 4A11-4A3 against SPI-3 was chosen
for use in all following experiments.
Site-directed mutagenesis of SPI-3
The four potential N-linked glycosylation sites (N161,
N188, N232, and N242) were mutated using the Altered
Sites mutagenesis system (Promega Corp.) following the
manufacturer’s instructions. The fully sequenced CPV
SPI-3 gene was cloned into the pAlter-Ex1 vector using
EcoRI and HindIII. The following 5-phosphorylated oligos
were used to mutate each of the four N-linked glycosylation
sites, with mismatched bases indicated by underlining. FS55
(5-pCTACTATGCTCGAGGATAATACTCTATG) was
used to mutate asparagine 161 to aspartic acid (N161D).
Note that for screening purposes the neighboring aspartic
acid 160 was changed to glutamic acid 160. This primer
introduces a new XhoI site that was used for screening
purposes. FS56 (5-pGATATCACTAAAACGCGCGAT-
GCTAGTTTTAC) was used to mutate asparagine 188 to
aspartic acid (N188D) and introduces a HhaI site used to
screen for mutants. FS57 (5-pCGTATAAGGATGCT-
GATATCAGTATGTACCTGGC) was used to mutate as-
paragine 232 to aspartic acid (N232D) and adds a new
EcoRV site. FS58 (5-pGGCAATAGGTGATGATAT-
GACTCATTTC) was used to mutate asparagine 242 to
histidine (N242H) and introduces a NdeI site used for
screening purposes. These mutagenic primers were used to
construct individual mutants of SPI-3 deficient in each of
the four N-linked glycosylation sites. To construct a mutant
deficient in all four N-linked glycosylation sites, the follow-
ing strategy was used. FS55 and FS56 were used to create
pAlter-Ex1 SPI-3 N161D N188D. FS57 and FS58 were
used to create pAlter-Ex1 SPI-3 N232D N242H. Both plas-
mids were cut with SalI and the 1.1 kb DNA fragment from
pAlter-Ex1 SPI-3 N161D N188D was ligated to the 0.824
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kb piece of DNA from pAlter-Ex1 SPI-3 N232D N242H to
generate pAlter-Ex1 SPI-3 N-glycosylation (). SPI-3 N-
linked glycosylation mutants were subcloned from pAlter-
Ex1 into pTM1-SPI-3 using BsrGI and BglII. To generate a
mutant of SPI-3 lacking the N-terminal signal sequence,
SPI-3 from pAlter-Ex1 was amplified using oligos FS252
(5GCATGCCATGGCATATCGTCTGCAAGGATTT-
ACC3) and FS256 (5GCGCGCGGATCCTTAAG-
GAGATTCCACCTTACC3). FS252 eliminates 15 N-
terminal amino acids of SPI-3 and introduces an NcoI site.
This PCR product as well as pTM1 were digested with NcoI
and BamHI and ligated to generate pTM1-SPI-3 signal
sequence (). All plasmids were sequenced to verify ap-
propriate nucleotide changes.
In vitro transcription, translation, and complex formation
with urokinase
Production of 35S labeled SPI-3 protein derivatives was
carried out using the TNT T7 Quick Coupled Transcription/
Translation system (Promega Corp.) as directed by the man-
ufacturer using pTM1-SPI-3, pTM1-SPI-3 N-glyc() and
pTM1-SPI-3 SS() as the DNA template. To analyze the
ability of radiolabeled SPI-3 protein to complex in vitro
with urokinase, 3 l of 35S labeled SPI-3 protein made in
the TNT system were incubated with buffer alone or with
0.25 l (7.5 U) of human urine low molecular weight
urokinase (Calbiochem, La Jolla, CA) in a total volume of
12 l at 37°C for 30 min. Reactions were stopped by
addition of 6 SDS sample buffer plus BME and boiling
for 3 minutes. Samples were then separated on SDS–10%
polyacrylamide gels which were fluorographed with Am-
plify, and the radiolabeled proteins visualized by autora-
diography. Intensity of bands was quantified using
ImageQuant 5.0 on a Molecular Dynamics STORM phos-
phorimager.
Expression of SPI-3 site directed mutants in the vaccinia
virus T7 system
To demonstrate that all 4 potential N-linked glycosyla-
tion sites were used in SPI-3, we made use of a vaccinia
virus infection/transfection system. Specifically, CV-1 cells
were infected with media alone or with vTF7-3, a vaccinia
virus expressing the T7 RNA polymerase from the poxvirus
P7.5 promoter (Fuerst et al., 1986), at an m.o.i. of 10. After
a 1 h adsorption, virus was removed and cells were washed
2 times with 3 ml of media minus serum. 1 ml of media
minus serum was then added to cells. 5 g of DNA (wild-
type or mutant SPI-3 in pTM1 vectors) was mixed with 12
l of LipofectACE (GIBCO-BRL) in a total volume of 100
l. The transfection mixture was added to cells and cells
were returned to 37°C. Media was removed at 17 h p.i. and
300 l of Eagle’s MEM without cysteine or methionine
(Sigma, St. Louis, MO) and 4.8 l of 5M NaCl were added
for 20 min to starve the cells of cysteine and methionine. To
radiolabel proteins, 30 Ci of 35S were added per sample
and cells were pulse-labeled for 30 min at 37°C. Media was
then removed and 1 ml ice-cold PBS was added to cells.
Cells were scraped into PBS and spun for 1 min at 8,200 g
in a microcentrifuge to pellet cells. Supernatant was dis-
carded and cells were resuspended in 100 l of lysis buffer
(100 mM Tris–HCl pH 8.0, 100 mM NaCl, 0.5% Triton
X-100) plus 0.2 mM PMSF and incubated on ice for 5 min.
Lysed cells were spun for 5 min at 11,500 g in a microcen-
trifuge and supernatant was removed for analysis. 10 l of
extracts were mixed with 6 SDS–PAGE sample buffer
including 100 mM BME and boiled for 5 min. Samples
were run on a SDS-polyacrylamide gel. Proteins were en-
hanced using Amplify (Amersham Pharmacia Biotech, Pis-
cataway, NJ) and detected by autoradiography.
Construction of recombinant CPV expressing mutant
SPI-3 proteins
A CPV derivative containing a SPI-3 gene lacking the
signal sequence was isolated by cloning DNA upstream
from the SPI-3 gene into a plasmid containing SPI-3 SS(),
and then inserting a P7.5-gpt cassette (confers resistance to
mycophenolic acid) in the plasmid vector to allow for tran-
sient dominant selection (Falkner and Moss, 1990). Specif-
ically, SPI-3 SS() was excised from pTM1-SPI-3 SS()
by digestion with NcoI and PstI, and inserted into
pGEM5Zf() (Promega Corp.) digested with the same en-
zymes. The flank upstream from SPI-3 was PCR amplified
from genomic wtCPV DNA with primers FS363 (5-GAC-
CTGCATGCTATACTGCGACGAGATACAACC-3) and
FS356 (5-GTCTAATTTTGCAGCCGTG-3), digested
with SphI and BspHI, and inserted into the SphI and NcoI
sites of pGEM5Zf() SPI-3 SS(). Finally a BamHI frag-
ment containing P7.5-gpt was inserted into the BamHI site of
the resulting plasmid to give pGEM5Zf() SPI-3 SS()
P7.5-gpt. To create recombinant virus, CV-1 cells were in-
fected with wt CPV and transfected with pGEM5Zf()
SPI-3 SS() P7.5-gpt in the presence of 2.5 g/ml myco-
phenolic acid (Sigma). The resulting recombinant virus
CPV SPI-3 SS() was plaque purified three times and
verified by PCR analysis and sequencing.
The CPV SPI-3 N-glyc() recombinant was obtained by
infecting cells with CPVSPI-3, transfecting with pTM1-
SPI-3 N-glyc(), and selecting for viruses that had lost the
gpt cassette by reverse gpt selection (Isaacs et al., 1990).
HGPRT(–)D98R HeLa cells (Kerr and Smith, 1991) were
used for this purpose, with 6-thioguanine at 50 M. The
resulting viruses were plaque purified three times and were
verified by PCR analysis and sequencing to confirm that all
four glycosylation site mutations, which lie within the re-
gion deleted in CPVSPI-3, were present.
CPV N-glyc()HA was constructed by infecting CV-1
cells with CPV N-glyc(), transfecting with pHGN4.1, a
plasmid containing gpt inserted into the HA gene, and
selecting for viruses that were resistant to 2.5 g/ml myco-
phenolic acid. Recombinant virus was plaque purified three
times. Loss of the HA gene was confirmed by analyzing
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infected CV-1 cells for the loss of the ability to agglutinate
chicken red blood cells.
Immunofluorescence
CV-1 cells were grown on glass slides and were infected
with media alone or infected with CPV, CPVSPI-3, CPV
SPI-3 N-glyc(), CPV SPI-3 SS(), or CPVHA at an
m.o.i. of 10. Virus was adsorbed for 1 h, removed, then
replaced with media. At the appropriate time p.i., culture
media was removed and cells were rinsed twice with PBS.
Cells were then fixed by addition of 4% paraformaldehyde
for 10 min at room temperature. To permeabilize cells,
methanol was added for 2 min at room temperature fol-
lowed by 2 washes with PBS. (Note that cells were only
permeabilized in Fig. 6 to enhance access to intracellular
compartments. All other immunofluorescence experiments
were done without permeabilization.) Cells were then
blocked by addition of PBS plus 3% BSA for 10 min at
room temperature. The following primary antibodies were
then added to cells either singly or in combination for 1 h at
room temperature and if necessary, were diluted into PBS
plus 3% BSA. Monoclonal antibody 4A11-4A3 which rec-
ognizes SPI-3 protein was used as undiluted hybridoma
supernatant. Polyclonal antibody to the mannose-6-phos-
phate receptor (Dr. William Dunn, University of Florida)
was diluted 1:100 in PBS plus 3% BSA for single labeling
or in MAb 4A11-4A3 for double labeling. Polyclonal anti-
body to the vaccinia virus HA protein (Dr. Samuel Dales)
was diluted 1:200 in PBS plus 3%BSA for single labeling or
in MAb 4A11-4A3 for double labeling. After primary an-
tibody incubation, cells were washed 3 times with PBS.
Cells were then stained by addition of goat anti-mouse
conjugated to FITC and/or goat anti-rabbit conjugated to
Texas Red (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA) diluted 1:100 in PBS plus 3% BSA for 30
min at room temperature. Cells were then washed 3 times
with PBS and mounted with Vectashield with or without 1.5
g/ml DAPI (Vector Laboratories, Burlingame, CA). Cov-
erslips were added to slides and sealed prior to microscopy.
Samples were examined with a Zeiss Axioplan 2 Fluores-
cence Microscope or a Bio-Rad MRC 1024 confocal laser
scanning microscope.
Preparation of infected cell extracts and supernatants for
Western Blot analysis
CV-1 cells (2.6  106 cells per well) were mock infected
with medium alone or infected with wt CPV or various CPV
mutants at an m.o.i. of 10. Virus was adsorbed for 1 h at
37°C. Inoculum was removed, 1 ml of media minus serum
was added per well and dishes were returned to 37°C. At
20 h post infection, media was removed, and spun for 5 min
at 2,500 g to pellet cells. Supernatant was then spun for 20
minutes at 16,000 rpm in a Beckman JA-20 rotor to pellet
EEV. Processed supernatant was transferred to a new tube.
To process infected cells, 1 ml of PBS was added to the
monolayer and cells were scraped into the buffer. Cells were
pelleted for 5 min at 2500 g. PBS was removed and 50 l
of cell lysis buffer (100 mM Tris–HCl pH 8.0, 100 mM
NaCl, 0.5% Triton X-100) plus 0.2 mM PMSF was added.
Cells were vortexed and placed on ice for 20 min to lyse
cells. Solution was spun for 15 min at maximum speed in a
microcentrifuge to pellet insoluble material. The remaining
soluble infected cell extract was removed to a new tube. For
Western Blot analysis, cell equivalents of supernatant and
pellet were mixed with 6 SDS loading buffer including
100 mM BME, boiled for 5 min and run on a 10% SDS-
polyacrylamide gel. Gels were transferred to Nitrobind ni-
trocellulose (MSI, Westborough, MA) and blocked over-
night in blocking solution (5% non-fat dry milk, 0.1%
Tween in TBS: 150 mM NaCl, 20 mM Tris pH 8.0) at 4°C.
Membranes were probed with a 1:50 dilution of SPI-3
monoclonal antibody 4A11-4A3 in blocking solution for
1 h. Blots were washed for 1 h with 6 changes of wash
buffer (0.1% Tween in TBS) then incubated with a 1:2000
dilution of HRP-conjugated goat anti-mouse secondary an-
tibody (Sigma) in blocking solution for 1 h. Again, blots
were washed for 1 h with 6 changes of wash buffer (0.1%
Tween in TBS) and membranes were developed using the
ECL plus system (Amersham Pharmacia Biotech, Inc., Pis-
cataway, NJ) following manufacturer’s instructions.
Electron microscopy
CV-1 cells were infected with wt CPV or CPVSPI-3 at
a m.o.i. of 5, and unabsorbed virus removed after 2 h by two
washes with serum-free medium before the addition of
medium containing serum. EEV was recovered at 18 h p.i.
by removing the medium gently, spinning twice at low
speed to remove cells, and then pelleting the extracellular
virus by centrifugation at 15,000 rpm in a Beckman SW 28
rotor for 1 h at 4°C. Extracellular virus was partially puri-
fied by spinning through a 17 ml 36% sucrose cushion at
13,200 rpm in an SW28 rotor for 1.5 h at 4°C. Intracellular
virus was prepared by harvesting infected cells at 18 h p.i.,
washing in PBS, and swelling on ice in 10 mM Tris–HCl,
pH 8.0 before Dounce homogenization with 20 strokes.
Nuclei were removed by centrifugation for 5 min at 500 g.
Intracellular virus was partially purified from the superna-
tant by spinning through a sucrose cushion as above.
10 l drops of virus containing approximately 107 pfu
were placed on Parafilm and adsorbed for 10 min to carbon-
coated 400-mesh grids. The grids were washed by floating
on 4 drops (50 l) of PBS/0.2% glycine for 8 min total,
blocked in PBS/1% BSA for 10 min, and then reacted with
the primary antibody by floating on a 25 l droplet of
PBS/1% BSA containing a 1:50 dilution of purified anti-
SPI-3, anti-B5R (mAb 20), or anti-14kDa (mAb C3) for 2 h.
Following 6 washes with PBS over 10 min, the grids were
floated on a 25 l droplet of a 1:30 dilution of 12 nm
gold-conjugated goat anti-mouse IgG antibody (Jackson Im-
munoResearch Laboratories, Inc.) for 1 h, washed in 6 drops
of PBS, fixed in 2% paraformaldehyde for 10 min, washed
in H2O for 5 min, and stained in 0.5 % uranyl acetate for
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30 s. The whole-mount grids were viewed with a Hitachi
H-7000 transmission electron microscope.
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